关节镜下肩袖修复术中应用唑来膦酸:一项前瞻性随机安慰剂对照II期试验的短期结果
这项单中心、前瞻性、随机、安慰剂对照、三盲II期试验纳入80例无骨质疏松的关节镜下肩袖修复患者,术中随机接受单剂唑来膦酸或对照,6个月时唑来膦酸组再撕裂率显著低于对照组(15% vs 35%,P=0.001),功能评分更优,作者认为唑来膦酸是安全、易用、经济的增强技术。
要点
- 6个月再撕裂率唑来膦酸组15%(6/40)显著低于对照组35%(14/40),P=0.001。
- 唑来膦酸组再撕裂风险RR 0.43(95%CI 0.16-0.98),OR 0.328(95%CI 0.111-0.969,P=0.044)。
- 术后冈上肌脂肪浸润唑来膦酸组显著低于对照组(P<0.001)。
核心结论
- 术中全身单剂唑来膦酸可减少关节镜下肩袖修复术后再撕裂;作者认为唑来膦酸是安全、易用、经济的增强技术。
研究设计与样本
- 单中心、前瞻性、随机、安慰剂对照、三盲II期试验,证据等级1级,共80例患者术中随机分为唑来膦酸组(n=40)和对照组(n=40),所有患者术后6个月行磁共振成像。
主要发现
- 6个月时再撕裂唑来膦酸组(n=6;15%)显著低于对照组(n=14;35%),P=0.001。
- 唑来膦酸组再撕裂风险RR 0.43(95%CI 0.16-0.98),OR 0.328(95%CI 0.111-0.969,P=0.044)。
- 术后冈上肌脂肪浸润唑来膦酸组显著低于对照组,P<0.001。
- 两组术后3个月和6个月临床与功能结果均显著改善;末次随访时唑来膦酸组在肩外展(P=0.002)、前屈(P=0.002)、外旋(P=0.001)、Constant-Murley评分(P<0.001)、美国肩肘外科医师评分(P<0.001)、主观肩关节价值(P<0.001)和疼痛视觉模拟评分(P<0.001)方面更优。
关键数值与推荐
- 术中全身单剂唑来膦酸;再撕裂率唑来膦酸组15%(6/40)vs 对照组35%(14/40),P=0.001。
- 再撕裂风险RR 0.43(95%CI 0.16-0.98),OR 0.328(95%CI 0.111-0.969,P=0.044)。
- 术后冈上肌脂肪浸润唑来膦酸组显著低于对照组,P<0.001。
临床怎么用
- 作者认为,唑来膦酸是关节镜下肩袖修复患者安全、易用且经济的增强技术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite technical innovations and surgical improvements, retear rates after arthroscopic rotator cuff (RC) repair remain high. Preclinical studies demonstrated improved outcomes using bisphosphonates after RC repair. PURPOSE/HYPOTHESIS: The purpose of this monocentric, prospective, randomized, placebo-controlled, triple-blinded phase II trial was to investigate retears in patients without osteoporosis undergoing arthroscopic RC repair with a systemic single-dose zoledronic acid. It was hypothesized that zoledronic acid would reduce retears after RC repair. STUDY DESIGN: Randomized controlled trial; Level of evidence, 1. METHODS: A total of 80 patients were intraoperatively randomized to the zoledronic acid group (n = 40) or the control group (n = 40). All patients underwent magnetic resonance imaging 6 months after surgery. Range of motion, abduction strength, Constant-Murley score (CMS), American Shoulder and Elbow Surgeons (ASES) score, Subjective Shoulder Value (SSV), and Visual Analog Scale (VAS) for pain were assessed preoperatively as well as 3 and 6 months after arthroscopic RC repair. RESULTS: At 6 months, retears were significantly lower (P = .001) in the zoledronic acid group (n = 6; 15%) compared with the control group (n = 14; 35%). The risk of a RC retear with an additional zoledronic acid treatment (RR, 0.43 [95% CI, 0.16; 0.98]) was significantly lower compared with that of the control group (OR, 0.328; 95% CI, 0.111-0.969; P = .044). Postoperative fatty muscle infiltration of the supraspinatus was significantly lower in the zoledronic acid group compared with the control group (P < .001). Clinical and functional outcomes significantly improved in the 2 study groups 3 and 6 months postoperatively, with better outcomes for abduction (P = .002), forward flexion (P = .002), external rotation (P = .001), CMS (P < .001), ASES score (P < .001), SSV (P < .001), and VAS for pain (P < .001) in the zoledronic acid group at the final follow-up. CONCLUSION: An intraoperative systemic single-dose zoledronic acid reduced retears after arthroscopic RC repair. Zoledronic acid is a safe, easy-to-apply, and cost-effective augmentation technique for patients undergoing arthroscopic RC repair. REGISTRATION: NCT05677152 (ClinicalTrials.gov identifier).
引用
- Schanda JE, Ullrich R, Boesmueller S, et al. Intraoperative Zoledronic Acid for Arthroscopic Rotator Cuff Repair: Short-Term Results From a Prospective, Randomized, Placebo-Controlled Phase II Trial. Am J Sports Med. 2026. PMID: 41549490. doi:10.1177/03635465251399167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。